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Glypican-3 (GPC3) is an emerging therapeutic target in hepatocellular carcinoma (HCC), even though
the biological function of GPC3 remains elusive. Currently human (MDX-1414 and HN3) and human-
ized mouse (GC33 and YP7) antibodies that target GPC3 for HCC treatment are under different stages
of preclinical or clinical development. Humanized mouse antibody GC33 is being evaluated in a
phase II clinical trial. Human antibodies MDX-1414 and HN3 are under different stages of preclinical
evaluation. Here, we summarize current evidence for GPC3 as a new target in liver cancer, discuss
both its oncogenic function and its mode of actions for current antibodies, and evaluate potential
challenges for GPC3-targeted anti-cancer therapies.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Hepatocellular carcinoma (HCC) is a high-ranking
malignancy with limited treatment modalities
Liver cancer is the ﬁfth most prevalent cancer in the world and
the third most frequent cause of cancer-related death [1–3]. Both
the incidence and associated-mortality of liver cancer are rising.
Hepatocellular carcinoma (HCC) is the major form of liver cancer,
accounting for 90% of all liver cancers, and resulting in at least
500000 deaths per year [4]. The overall 5-year relative survival
rate for patients with liver cancer is about 15% in the US
(www.cancer.org). Liver cancer is usually resistant to most chemo-
therapy drugs [5]. Potential curative therapeutic approaches are
available only for cases in which the diagnosis is done at an asymp-
tomatic early stage [3], which constitutes only 37% of patients. In
vivo imaging and surveillance of individuals with high risk are
most utilized strategies for early detection of hepatic nodules [6],
while histological examination of biopsy samples for tumor
markers (such as HSP70) could signiﬁcantly increase the diagnosis
accuracy [7]. The major risk factors of HCC include cirrhosis, hepa-
titis B- and hepatitis C-virus infection, non-alcoholic fatty liver
disease/non-alcoholic steatohepatitis (NAFLD/NASH), obesity, and
diabetes [8,9].2. GPC3 is a potential biomarker for both targeted therapy and
diagnosis of HCC
Glypican-3 (GPC3, also called as DGSX, GTR2-2, MXR7, OCI-5,
SDYS, SGB, SGBS, SGBS1, or heparan sulfate proteoglycan (HSPG)
is a member of the glypican family that attaches to the cell surface
by a glycosylphosphatidylinositol (GPI) anchor [10] (Fig. 1A). The
GPC3 core protein is a 70-kD protein, with a furin cleavage site
in the middle. Furin cleavage results in the formation of the
40-kD N-terminal fragment and the 30-kD C-terminal fragment
[11] (Fig. 1A). Recently, the crystal structure of Drosophila glypican
Dally-like (Dlp, a homolog to human GPC1) and human GPC1
showed that the N- and C-terminal domains of GPC1 are linked
by disulﬁde bonds [12,13]. Given that the glypican family (includ-
ing six members from GPC1 to GPC6) contains 14 highly conserved
cysteine residues, their three-dimensional structures are presumed
to be similar, indicating that the N- and C-terminal fragments of
GPC3 are very likely to be associated at the cell surface by intra-
molecular disulﬁde bonds.
2.1. GPC3 expression in HCC
Several studies have conﬁrmed that GPC3 is a potential liver
cancer therapeutic target because it is over-expressed in HCC but
not expressed or expressed at low levels in normal adult tissue
[14–16].
Hsu et al. performed pioneering work to identify GPC3 as a
potential biomarker for HCC [17]. By using an mRNA differential
Fig. 1. Therapeutic antibodies targeting GPC3 for liver cancer treatment. (A) Diagram illustration of GPC3 structure and the binding sites of the current antibodies. N, amino-
terminal domain. C, carboxyl-terminal domain. HS, heparan sulfate. (B) The mechanism of HN3 antibody function. In the absence of HN3, growth factors bind to GPC3 and
promote cell proliferation. In the presence of HN3, HN3 blocks the binding of growth factors and triggers intracellular signaling, leading to inactivation of YAP and inhibition
of cell proliferation in HCC.
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et al. found GPC3 mRNA highly expressed in 9 out of 14 HCC
samples, whereas none were detected in eight non-tumor liver
samples. This HCC speciﬁcity was further conﬁrmed by Northern
blot analysis in an expanded number of HCC samples, fetal and
adult normal tissues, as well as other adult tumor types. From
154 patients, 143 out of 191 (74.8%) primary and recurrent HCC
samples were GPC3 positive, but only 5 out of 154 (3.2%) non-
tumor liver samples had detectable GPC3 mRNA. In fetal tissues,
GPC3 mRNA level was high in lung, liver, kidney, and placenta,
and low in pancreas. In adult tissues, GPC3 mRNA only had low
expression in heart, lung, kidney, and ovary, and in trace amounts
in skeleton muscle, pancreas, small intestine, and colon [17].
Comparison of GPC3 with another established HCC marker,
alphafetoprotein (AFP), revealed a higher frequency of GPC3 mRNA
expression than serum AFP level (71.7% versus 51.3%) based on the
analysis of 113 patients with unicentric primary HCC. The
difference was even more signiﬁcant when tumor size was below
3 cm (77% for GPC3 versus 43% for AFP) [17].
By using Northern blot and in situ hybridization, Zhu et al. also
found that GPC3mRNAwas either low or absent in normal liver, fo-
cal nodular hyperplasia (FNH), and in liver cirrhosis [16]. In contrast,
expression of GPC3 mRNA was markedly increased in 20 out of 30
HCC samples and moderately increased in ﬁve out of 30 HCC sam-
ples. The average increase in GPC3 mRNA expression in HCC was
21.7-fold compared with expression in normal liver, and 7.2- and
10.8-fold, respectively in comparison with FNH or liver cirrhosis.
Filmus et al. later on conﬁrmed GPC3 expression in HCC pa-
tients at the protein level by a mouse monoclonal antibody
(1G12) against a GPC3 C-terminal peptide [18]. By using immuno-
histochemistry staining and ELISA method, Filmus et al. found
GPC3 over-expressed in 72% of HCC (21 out of 29) based on immu-
nohistochemistry, and 53% (18 out of 34) of HCC patients had ele-
vated GPC3 level in serum (151–2924 ng/ml), while it is
undetectable in healthy donors. Since then, more and more studies,
majorly based on immunohistochemistry, convinced that GPC3
could be a marker for routine histological examination and poten-
tially as targets in monoclonal antibody-based hepatocellular car-
cinoma therapy. Yamauchi et al. developed two other GPC3
monoclonal antibodies, GPC3-C02 and A1836A, and performed
GPC3-immunohistochemistry in the pathological diagnosis of be-
nign and malignant hepatocellular lesions with formalin-ﬁxedand parafﬁn-embedded specimens [19]. Diffusely positive staining
of GPC3 was observed in malignant hepatocytes in hepatoblasto-
mas and in hepatocellular carcinomas (47/56, 84%), and the
expression of GPC3 was independent of the differentiation and size
of the hepatocellular carcinoma [19].
GPC3 may also be used as an ancillary tool in the histopatho-
logic diagnostic process to distinguish HCC from cirrhosis, dysplas-
tic nodules, and focal nodular hyperplasia-like nodules [20].
Libbrecht et al. performed immunohistochemistry and real-time
reverse transcriptase-polymerase chain reaction studies on 59
HCCs with a diameter less than or equal to 3 cm present in the cir-
rhotic liver of 66 patients and in patients from 16 low-grade dys-
plastic nodules, 33 high-grade dysplastic nodules, and 13 focal
nodular hyperplasia-like nodules [20]. It was found that GPC3
expression was higher in small HCCs than in cirrhosis and other
types of small focal lesions, indicating that the transition from pre-
malignant lesions to small HCC is associated with a sharp increase
of GPC3 expression in a majority of cases. The sensitivity and spec-
iﬁcity of a positive GPC3-staining for the diagnosis of HCC in small
focal lesions was 77% and 96%, respectively, in resected cases, and
83% and 100%, respectively, for needle biopsies. [20]. Similar re-
sults were also reported by Wang et al. who used immunohisto-
chemistry on 54 HCCs and adjacent liver tissues (21 developing
from cirrhosis and 33 from normal liver) and 94 cirrhotic macro-
nodules [21]. GPC3 staining was observed in 19 (90%) of 21 HCC
cases with cirrhosis and in 18 (64%) of 28 HCC cases with normal
liver. Among the 94 macronodules, GPC3 immunostaining was
noted in 48% (14/29) of high-grade dysplastic or early HCC and
in 3% (2/65) of benign or low-grade dysplastic macronodules, indi-
cating GPC3 may be used to identify some cirrhotic macronodules
with malignant potential. Baumhoer et al. used tissue microarray
immunohistochemical technology to investigate 4387 tissue sam-
ples from 139 tumor categories and 36 non-neoplastic and prene-
oplastic tissue types [14]. GPC3 expression was detected in 9.2% of
non-neoplastic liver samples (11/119), 16% of preneoplastic nodu-
lar liver lesions (6/38), and 63.6% of HCCs (140/220), indicating
GPC3 could differentiate HCC from non-neoplastic and preneoplas-
tic liver disease. Furthermore, several other tumors also revealed
GPC3 expression, including squamous cell carcinoma of the lung
(27/50, 54%), testicular non-seminomatous germ cell tumors (32/
62, 52%), and liposarcoma (15/29, 52%) [14]. Coston et al. studied
the expression of GPC3 and CD34 in 107 cases of HCC, 19 cases
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(FNH), and 225 cases of non-hepatic human tumors with epithelial
differentiation [22]. Ninety-four of 107 cases (88%) of HCC showed
focal or diffuse cytoplasmic GPC3 staining, whereas all HA and FNH
cases were GPC3-negative, and only 7 of 225 cases (3%) of non-he-
patic tumors with epithelial differentiation expressed GPC3. This
data indicates that GPC3 is a very speciﬁc marker not only for dif-
ferentiating HCC from non-hepatic tumors with epithelial differen-
tiation, but also for differentiating HCC from HA and FNH [22].
Wang et al. studied 111 HCCs, 48 hepatocellular adenomas, 30 fo-
cal nodular hyperplasias, and 32 large regenerative nodules in the
background of cirrhosis [23]. It was found that cytoplasmic, mem-
branous, and canalicular GPC3 staining was detected in 84 (75.7%)
of the 111 HCCs. In contrast, none of the 110 cases of hepatocellu-
lar adenoma, focal nodular hyperplasia, and large regenerative
nodule showed detectable GPC3 staining. GPC3 expression in HCCs
did not correlate with the size, differentiation, or stage of the tu-
mors, the presence or absence of cirrhotic background, or the
underlying etiologies [23]. Many other studies have similarly
shown that GPC3 is highly and speciﬁcally expressed in 70–100%
cases of HCC, and could be used as a maker to differentiate HCC
from benign liver tissues [24–28].
2.2. Combination of GPC3 with other markers for histological diagnosis
of HCC
Since one marker may not be sufﬁcient to detect all HCC cases,
adoption of a panel of HCC markers may be a good choice. The
most common combination of HCC markers is GPC3, HSP70 and
glutamine synthetase (GS) [7,29,30]. Di Tommaso analyzed 52 sur-
gically removed non-malignant hepatocellular nodules (15 large
regenerative (LRN), 15 low grade dysplastic (LGDN), 22 high grade
dysplastic (HGDN) and 53 HCCs (10 early, 22 grade 1, and 21 grade
2–3) by immunostaining them for HSP70, GPC3, and GS [29]. The
sensitivity and speciﬁcity of the individual markers for the detec-
tion of early HCC grade 1 (eHCC-G1) were 59% and 86% for GS,
69% and 91% for GPC3, and 78% and 95% for HSP70. Using a 3-mar-
ker panel with a minimum of two positives, (regardless of which),
the sensitivity and speciﬁcity for the detection of eHCC-G1 were
respectively 72% and 100%. The most sensitive combination was
HSP70+/GPC3+ (59%) when a 2-marker panel was used. In contrast,
the combination of three positive markers revealed a negative
detection of 100% LRN and LGDN, 73% HGDN and 3% eHCC-G1 [29].
2.3. GPC3 as a serum marker
Although GPC3 is a cell-surface marker, it can also be released
into the serum by a lipase called Notum that cleaves the GPI anchor
[31]. Therefore, GPC3 also showed diagnostic values as a serum
marker [32,33]. Qiao et al. compared the serum level of three mark-
ers, GPC-3, Human-Cervical-Cancer-Oncogene (HCCR) and a-feto-
protein (AFP), for diagnosing HCC in 189 samples (101 cases of
HCC, 40 cases of cirrhosis, 18 cases of hepatitis and 30 cases of con-
trol healthy donors). It was found that GPC-3 was the best marker.
Using 26.8 ng/ml as the cut-off for HCC diagnosis, GPC-3 had a sen-
sitivity of 51.5% and a speciﬁcity of 92.8%. HCCR reached a sensitiv-
ity of 22.8% and a speciﬁcity of 90.9% if the cut-off was set as
58.8 mAU/ml. The efﬁcacy and sensitivity of AFP were 36.6% and
98.5% when using 199.3 ng/ml as the cut-off. No signiﬁcant correla-
tion was found between these three markers. Simultaneous detec-
tion of three markers signiﬁcantly increased the sensitivity to
80.2%, much higher than AFP alone [33]. Chen et al. also measured
serum GPC3 in a total of 1037 subjects, including 155 patients with
HCC, 180 with chronic hepatitis, 124 with liver cirrhosis, 442 with
non-HCC cancer and 136 healthy controls. The average level of ser-
um GPC3 (sGPC3) in HCC patients was 99.94 ± 267.2 ng/ml, whichwas signiﬁcantly higher than in patients with chronic hepatitis
(10.45 ± 46.02 ng/ml), liver cirrhosis (19.44 ± 50.88 ng/ml), non-
HCC cancer (20.50 ± 98.33 ng/ml) and healthy controls
(4.14 ± 31.65 ng/ml) [32]. In addition to full length GPC3, Hippo
et al. found the N-terminal portion of GPC3 (GPC3N) is cleaved
and secreted into serum, therefore the GPC3N fragment may also
serve as a serological marker [34]. However, the serum level of
GPC3N fragment (4.84 ± 8.91 ng/ml in HCC versus 1.09 ± 0.74 ng/
ml in liver cirrhosis, and 0.65 ± 0.32 ng/ml in healthy controls) is
much lower than that of the full-length protein.3. GPC3 promotes the growth of HCC by stimulating oncogenic
signaling pathways
GPC3 was initially discovered from a patient with Simpson–
Golabi–Behmel syndrome (SGBS), a rare X-linked overgrowth
disease [35], which is caused by loss-of-function mutations.
GPC3-deﬁcient mice display developmental overgrowth and some
of the abnormalities typical of SGBS [36]. In transgenic mice, over-
expression of GPC3 suppresses hepatocyte proliferation and liver
regeneration [37].
At the cellular level, GPC3 may act as a co-receptor or storage
pocket for several growth factors, including Wnts [38,39], Hedge-
hogs [40,41], ﬁbroblast growth factors (FGFs) [42], and bone mor-
phogenetic proteins [43], therefore regulating the interaction of
these growth factors to their cell-surface receptors. This may ex-
plain the observation that cell-surface GPC3 promoted the growth
of HCC cells in the following two studies [44,45]. First, HCC cells in-
fected with lentivirus expressing soluble GPC3 (a secreted form
that lacks the GPI anchoring domain) have a lower cell prolifera-
tion rate [44], suggesting that the soluble GPC3 protein secreted
by infected cells may inhibit cell proliferation in an autocrine man-
ner by competing the binding of grow factors with endogenous
cell-surface GPC3. To conﬁrm this, our group produced recombi-
nant GPC3 (GPC3DGPI, amino acid residues Q25-H559) and found
that recombinant GPC3 protein, functioning as a dominant-nega-
tive form, inhibited the growth of HCC in vitro [45]. In addition,
silencing GPC3 expression by siRNA or shRNA in HCC cell lines
HepG2, Hep3B, Huh-7 and Huh-4 can inhibit cell proliferation
[46,47]. Sun et al. performed transient transfection of Huh-7 and
HepG2 cells with GPC3 siRNA, and found suppression of GPC3 in-
duced upregulation of TGF-b2 [46]. Furthermore, addition of hu-
man recombinant TGF-b2 to HCC cells in culture prevented cell
growth, and cotransfection of siRNA-GPC3 with siRNA-TGF-b2 par-
tially attenuated the effects of GPC3 suppression on cell prolifera-
tion, cell cycle progression, apoptosis, and replicative senescence,
indicating the involvement of TGF-b2 in siRNA-GPC3-mediated
growth suppression [46].4. Antibodies that are therapeutically targeting GPC3
To date, several mouse monoclonal antibodies (mAb) against
GPC3 have been produced [18,19,34,48–52], and almost all of them
target a peptide derived from GPC3. However, none of these anti-
bodies have shown the ability to inhibit HCC cell proliferation or in-
duce apoptosis. Consequently, they are used as a research tool, with
the exception of GC33, which is currently being developed as a po-
tential therapeutic agent. Together, four GPC3 antibodies including
GC33 are being developed for liver cancer therapy (Table 1).
4.1. GC33: the ﬁrst humanized mouse antibody being evaluated in
clinical trial
GC33 recognizes a C-terminal peptide of GPC3 [50,51] (Fig. 1A).
Humanized GC33, as a single agent, has passed phase I clinical tri-
Table 1
Current therapeutic monoclonal antibodies targeting GPC3 in liver cancer.
Antibody
name
Species Antibody
form
Epitope Mechanism of action Development
status
Antibody developer References
GC33 Mouse
(humanized)
IgG Linear, C-terminal
(residues 524–563)
ADCC Phase II Chugai Pharmaceutical
Co. Ltd. and Roche
[50–54]
YP7 Mouse
(humanized)
IgG Linear, C-terminal
(residues 511–560)
ADCC Preclinical NCI [49]
HN3 Human VH-hFc Conformational,
both N- and C-
terminal domains
Inhibition of YAP signaling; direct
inhibition of HCC cell proliferation;
ADCC
Preclinical NCI [47]
MDX-1414 Human IgG N/A N/A Preclinical Bristol-Myers Squibb
Co.
AACR.2009
(Abstract#
1223), 58
N/A, not available.
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NCT00746317) [53]. More clinical trials for GC33 in combination
with FDA-approved chemo-drug sorafenib (phase I, ClinicalTri-
als.gov Identiﬁer: NCT00976170) and GC33 alone (phase II, Clini-
calTrials.gov Identiﬁer: NCT01507168) are currently recruiting
volunteers. The mechanism of GC33 function is though antibody-
dependent cell cytotoxicity (ADCC), and GC33 can bring cytotoxic
inﬁltrating T-lymphocytes into tumor tissues [50,52,54].
GC33 exhibited marked tumor growth inhibition of subcutane-
ously transplanted HepG2 and Huh-7 xenografts [50]. In a phase I
trial, patients with measurable, histologically proven, advanced
HCC were enrolled to a dose-escalation study of GC33 (2.5–
20 mg/kg) given intravenously weekly. The results of 20 patients
showed that no maximum tolerated dose was reached as there
were no dose-limiting toxicities up to the highest planned dose le-
vel. Mean half-life (t1/2) was 2.94, 3.46, 5.16, and 6.47 days, at 2.5,
5, 10, and 20 mg/kg respectively. Median time to progression was
26.0 weeks in the GPC3 high expression group and 7.1 weeks in
the GPC3 low expression group. Stable disease of more than
26 weeks was observed in 4 of 15 (26.7%) patients and all of them
were in the GPC3 high expression group. Common adverse events
with all grades included fatigue (50%), constipation (35%), head-
ache (35%), and hyponatremia (35%). The incidence of adverse
events seemed not to be dose dependent. Overall, this phase I
study showed that GC33 was well tolerated in advanced HCC and
the preliminary clinical beneﬁt of GC33 warrants prospective eval-
uation [53]. In the ongoing phase II clinical trial, the dosing of GC33
is set as 1600 mg iv Day 1 and 8, and every 2 weeks thereafter
(ClinicalTrials.gov Identiﬁer: NCT01507168).
4.2. YP7: a new mouse anti-GPC3 antibody with high afﬁnity
Our lab generated a newmouse antibody (named YP7) via GPC3
peptide (a.a. 510–560) immunization and selected by high-
throughput cell binding screening by ﬂow cytometry [49]. YP7
has a single-digit picomolar afﬁnity for GPC3, and has much more
sensitive detection limit than the commercially available antibody,
1G12, in immunohistochemistry and Western blot. The epitope of
YP7 overlaps with that of GC33 (Fig. 1A). YP7 has in vivo tumor-
suppression activity and holds great potential for in vivo tumor
imaging as well as antibody therapies.
4.3. HN3: a human single-domain antibody that can directly inhibit
HCC cell proliferation
Ideally, therapeutic antibodies should have direct cell-growth
inhibition function by blocking important signaling pathways
(e.g., Herceptin), plus ADCC and CDC (complement-dependent
cytotoxicity). Conventional antibodies (i.e., Y-shaped antibodies
with full-length heavy chains and light chains) targeting GPC3 donot have direct inhibition properties, due speculatively to the dif-
ﬁculty of targeting the potentially cryptic functional epitope of
GPC3 by a conventional antibody. Domain antibodies (VH or VL do-
mains only) are able to target cryptic epitopes on antigens (e.g., the
clefts of enzymes and receptors) due to their small size [55–57].
Based on this rationale, a human heavy chain variable (VH) domain
antibody (HN3) targeting GPC3 was isolated and identiﬁed by
using phage display technology [47].
HN3 binds a unique conformational epitope in the native form
of GPC3 core protein on cancer cells with high afﬁnity (Fig. 1A).
HN3 binding requires both the N-terminus and C-terminus do-
mains of GPC3, and is independent of the HS chains on GPC3. This
feature distinguishes HN3 from all the known mAbs that recognize
either the N- or C-terminus of GPC3. Furthermore, the conforma-
tion of the HN3 binding site may affect a newly-discovered GPC3
function, since HN3 can directly inhibit HCC cell growth in several
HCC cell models and exhibited signiﬁcant HCC xenograft tumor
growth inhibition in nude mice. Our HN3 study suggests that it
is possible to inhibit HCC cell proliferation with an antibody that
neutralizes the proliferative function of GPC3 by targeting the
appropriate epitope. Due to the fact that HN3 is the ﬁrst mAb that
shows direct inhibition of cell proliferation, future GPC3 structural
studies are worthwhile to reveal the precise structure that HN3
recognizes.
In addition to the unique epitope that it targets, the mechanism
of HN3 function is also novel. The down-stream signaling pathway
of HN3 involves YAP inactivation and cell cycle arrest. YAP is an
oncogene that when knocked down in HCC cells, cell proliferation
becomes signiﬁcantly decreased. Over-expression of YAP-S127A, a
constitutively active form of YAP, completely abolished HN3 activ-
ity and promoted cell proliferation. How GPC3 regulates the YAP
pathway has not been described and only speculation may be
made on the extracellular event of HN3 function. A reasonable
assumption is that HN3 blocks the interaction of GPC3 with unde-
termined growth factors, triggering the intracellular inactivation of
YAP signaling, and eventually leading to cell proliferation inhibi-
tion (Fig. 1B).
HN3 has three unique properties that GC33 lacks – it can di-
rectly inhibit HCC cell proliferation, it is a single-domain antibody,
and it is a fully human protein. Due to these characteristics and its
unique mechanism, HN3 is an attractive addition to the existing
GPC3-targeted liver cancer therapies. Side-by-side studies to com-
pare GC33 and HN3 in both preclinical and clinical settings are
needed.
4.4. MDX-1414: human anti-GPC3 antibody in pre-clinical studies
Medarex, Inc. (Princeton, US, now owned by Bristol-Myers
Squibb Corporate, New York, US) generated a panel of fully human
anti-glypican-3 antibodies, from which a lead candidate,
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function and internalization properties. MDX-1414 demonstrated
anti-tumor efﬁcacy leading to signiﬁcant and durable suppression
of established subcutaneous tumors in a liver cancer xenograft
model with no evidence of toxicity (Li-Sheng Lu, Jon Terrett, Chin
Pan, Dapeng Yao, Colin Chong, Jerry Jiang, Pina Cardarelli, Yi Wu,
Haichun Huang, Tim Chen, Alasdair Bell, Mohan Srinivasan, Karla
Henning. Development of anti-Glypican-3 therapeutic antibodies.
Annual Proceedings of the AACR.2009, Abstract #1223). MDX-
1414 is being evaluated for preclinical development [58].
5. Potential problems for GPC3-targeted antibody therapies
Based on the knock-down and siRNA experimental results, GPC3
is not a lethal gene to HCC cells. Therefore, it remains to be estab-
lishedwhether anti-GPC3 antibodies can cause complete regression
of tumor growth. Both GC33 and HN3 cannot completely eliminate
tumors, nor does knocking down GPC3 work, therefore indicating
that the therapeutics of a naked antibodymay not be potent enough
for curative treatment of HCC. Strategies to overcome this problem
include combination with chemotherapy (e.g., sorafenib that has
been approved for HCC), and armed antibodies, such as antibody-
drug conjugates, bi-speciﬁc antibodies (e.g., anti-GPC3/anti-CD3),
and chimeric antigen receptor-T cell adoptive therapy.
Another question that has not been studied is the stability of
GPC3 expression after antibody treatment. It is possible that
treatment-survived cells may lose GPC3 expression to gain drug
resistance. To address this issue, adiditonal future studies on
GPC3 expression regulation are needed.
6. Concluding remarks
GPC3 is an attractive target for developing therapeutic antibod-
ies to treat HCC patients. However, its structure–function relation-
ship is not clear. Most GPC3-targeting antibodies, excluding HN3,
did not directly inhibit HCC cell growth. Our HN3 study suggests
that the direct tumor growth-inhibition is dependent on the func-
tional epitope of GPC3. Therefore, further structure-biology studies
of GPC3 will facilitate the discovery of new antibodies that may
have more potent tumor-suppression activity.
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